JP2018510648A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510648A5
JP2018510648A5 JP2017553005A JP2017553005A JP2018510648A5 JP 2018510648 A5 JP2018510648 A5 JP 2018510648A5 JP 2017553005 A JP2017553005 A JP 2017553005A JP 2017553005 A JP2017553005 A JP 2017553005A JP 2018510648 A5 JP2018510648 A5 JP 2018510648A5
Authority
JP
Japan
Prior art keywords
aav
optionally
aav2
raav
oversized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017553005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510648A (ja
JP6878299B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026486 external-priority patent/WO2016164609A2/en
Publication of JP2018510648A publication Critical patent/JP2018510648A/ja
Publication of JP2018510648A5 publication Critical patent/JP2018510648A5/ja
Priority to JP2021075526A priority Critical patent/JP2021118724A/ja
Application granted granted Critical
Publication of JP6878299B2 publication Critical patent/JP6878299B2/ja
Priority to JP2023097370A priority patent/JP2023116678A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017553005A 2015-04-08 2016-04-07 オーバーサイズアデノ随伴ベクターの産生 Active JP6878299B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021075526A JP2021118724A (ja) 2015-04-08 2021-04-28 オーバーサイズアデノ随伴ベクターの産生
JP2023097370A JP2023116678A (ja) 2015-04-08 2023-06-14 オーバーサイズアデノ随伴ベクターの産生

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144862P 2015-04-08 2015-04-08
US62/144,862 2015-04-08
US201562220067P 2015-09-17 2015-09-17
US62/220,067 2015-09-17
PCT/US2016/026486 WO2016164609A2 (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021075526A Division JP2021118724A (ja) 2015-04-08 2021-04-28 オーバーサイズアデノ随伴ベクターの産生

Publications (3)

Publication Number Publication Date
JP2018510648A JP2018510648A (ja) 2018-04-19
JP2018510648A5 true JP2018510648A5 (enExample) 2019-05-09
JP6878299B2 JP6878299B2 (ja) 2021-05-26

Family

ID=56943906

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553005A Active JP6878299B2 (ja) 2015-04-08 2016-04-07 オーバーサイズアデノ随伴ベクターの産生
JP2021075526A Withdrawn JP2021118724A (ja) 2015-04-08 2021-04-28 オーバーサイズアデノ随伴ベクターの産生
JP2023097370A Pending JP2023116678A (ja) 2015-04-08 2023-06-14 オーバーサイズアデノ随伴ベクターの産生

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021075526A Withdrawn JP2021118724A (ja) 2015-04-08 2021-04-28 オーバーサイズアデノ随伴ベクターの産生
JP2023097370A Pending JP2023116678A (ja) 2015-04-08 2023-06-14 オーバーサイズアデノ随伴ベクターの産生

Country Status (27)

Country Link
US (1) US10815497B2 (enExample)
EP (2) EP3280799B1 (enExample)
JP (3) JP6878299B2 (enExample)
KR (2) KR20250126875A (enExample)
CN (1) CN107864657A (enExample)
AU (3) AU2016245806A1 (enExample)
BR (1) BR112017021505A2 (enExample)
CA (1) CA2982123A1 (enExample)
CL (1) CL2017002537A1 (enExample)
CO (1) CO2017011344A2 (enExample)
CR (1) CR20170505A (enExample)
DK (1) DK3280799T3 (enExample)
EA (1) EA201792236A1 (enExample)
EC (1) ECSP17074016A (enExample)
ES (1) ES3008382T3 (enExample)
GT (1) GT201700214A (enExample)
HU (1) HUE069779T2 (enExample)
IL (3) IL283291B (enExample)
MX (1) MX2017012935A (enExample)
PE (1) PE20171800A1 (enExample)
PH (1) PH12017501836A1 (enExample)
PL (1) PL3280799T3 (enExample)
SG (3) SG11201708203UA (enExample)
TN (1) TN2017000431A1 (enExample)
TW (1) TWI707951B (enExample)
UY (1) UY36611A (enExample)
WO (1) WO2016164609A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
PE20181338A1 (es) 2015-09-24 2018-08-21 Biomarin Pharm Inc Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
US11518991B2 (en) 2017-02-24 2022-12-06 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN118956965A (zh) * 2017-05-19 2024-11-15 编码治疗公司 高活性调控元件
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス, インコーポレイテッド 操作されたdna結合タンパク質
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
EP4461814A3 (en) * 2018-10-12 2025-02-26 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
CN114302968A (zh) * 2019-08-29 2022-04-08 美国西门子医学诊断股份有限公司 用于检测aav脱落的试剂和方法
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN111218446B (zh) * 2019-12-25 2023-03-28 劲帆生物医药科技(武汉)有限公司 一种肝脏特异性启动子及其应用
EP4121567B1 (en) * 2020-03-16 2025-12-31 The University of North Carolina at Chapel Hill COMPOSITIONS AND METHODS FOR THE SELECTIVE DETECTION OF TUMOR-DERIVED VIRAL DNA
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
JP2023536148A (ja) 2020-07-30 2023-08-23 シェイプ セラピューティクス インク. Raavウイルス粒子の誘導産生のための安定な細胞株
US20220090130A1 (en) 2020-08-23 2022-03-24 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
JP2024534123A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
AR126845A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
EP4408874A1 (en) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
US12234472B2 (en) 2021-10-18 2025-02-25 Regeneron Pharmaceuticals, Inc. Eukaryotic cells comprising adenovirus-associated virus polynucleotides
US20240392318A1 (en) * 2023-04-26 2024-11-28 Sanofi Host cell lines and methods for identifying and using such host cell lines
WO2026083329A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof
WO2026083328A1 (en) 2024-10-18 2026-04-23 Precision Biosciences, Inc. Base editing nucleotide sequences using homology directed repair

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
WO2001027303A1 (en) 1999-10-12 2001-04-19 The University Of North Carolina At Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
SG10202108118RA (en) 2001-11-13 2021-08-30 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
WO2004075861A2 (en) 2003-02-26 2004-09-10 Children's Hospital, Inc. Recombinant adeno-associated virus production
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
KR101812813B1 (ko) 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 aav 벡터에 대한 개선된 정제 방법
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SG10202007803QA (en) 2011-02-17 2020-09-29 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
AU2013336601B2 (en) * 2012-10-26 2018-01-25 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
EP3770169A1 (en) * 2013-09-12 2021-01-27 BioMarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors
EP3137497B2 (en) 2014-05-02 2025-03-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
CN116019934A (zh) 2015-02-10 2023-04-28 建新公司 病毒颗粒至纹状体和皮质的增强递送
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造

Similar Documents

Publication Publication Date Title
JP2021118724A5 (enExample)
JP2018522529A5 (enExample)
JP2017509632A5 (enExample)
JP2022190081A5 (enExample)
JP6619454B2 (ja) キャプシド
JP2024009857A5 (enExample)
JP2021106619A5 (enExample)
JP2019116492A5 (enExample)
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2021526829A5 (enExample)
JP2021003120A5 (enExample)
WO2016137949A4 (en) Regulatable expression using adeno-associated virus (aav)
JP2024144435A5 (enExample)
JP2019503649A5 (enExample)
JP2022505106A5 (enExample)
CN105636981B (zh) 腺相关病毒因子viii载体
JP2021514659A5 (enExample)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2021523718A5 (enExample)
JP2021523702A5 (enExample)
JP2022542828A5 (enExample)
IL292264B2 (en) aav transfer cassette
JP2022551744A5 (enExample)
JP2022553307A5 (enExample)
CN120787264A (zh) 肝脏去靶向衣壳